The following is a preliminary list of readings, subject to revision. If you are accessing these readings from a computer off-campus, you may need to set up UBC VPN.
————————————————
BLOCK 1: Introduction to the Access Gap
Required readings:
1. Equitable access to essential medicines: a framework for collective action by the WHO
Suggested readings:
1. Drug patents under the spotlight: Sharing practical knowledge about pharmaceutical patents by MSF.
2. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries by Shanti Mendis et al.
3. Drug development for neglected diseases: a deficient market and a public-health policy failure by Patrice Trouiller et al.
————————————————
BLOCK 2: The Role of Governments
Required readings:
1. Patents: The global context, and how UAEM fits in – intro to patent law by Universities Allied for Essential Medicines
2. Implications of the Doha declaration on the TRIPS agreement and public health by the World Health Organization
Suggested readings:
1. Commission on Intellectual Property Rights final report. Chapter 2: Health.
2. TRIPs and patenting activity: Evidence from the Indian pharmaceutical industry by Alka Chadha.
3. The introduction of pharmaceutical product patents in India: heartless exploitation of the poor and suffering? by Jean O. Lanjouw.
4. Thailand and the compulsory licensing of efavirenz by Robert Steinbrook
5. Brazil puts Patients before Patents by James Love.
Merck and Co., Inc. Statement on Brazilian Government’s Decision to Issue Compulsory License for Stoctrin(tm)
6. Sustaining access to antiretroviral therapy in the less-developed world: lessons learned from Brazil and Thailand by Nathan Ford, David Wilson, et al.
7. Race against time: the export of essential medicines to Rwanda by Matthew Rimmer
————————————————
BLOCK 3: The Role of Non-Governmental Organizations
Required readings:
1. Beyond TRIPs: The role of non-state actors and access to essential medicines by Noah Novogrodsky.
Suggested readings:
1. Cost Benefit Analysis for UNITAID patent pool by UNITAID.
2. Clinton HIV/AIDS initiative: access programs and what they have accomplished
3. Gates Foundation: Grand Challenges in Global Health
4. MSF’s Access to Medicines Campaign
————————————————
BLOCK 4: The Role of Pharmaceutical Companies
1. Aligning pharmaceutical innovation with medical need by Carl Nathan
More readings for this block coming soon!
————————————————
BLOCK 5: The Role of Universities and Student Activism
Readings (required)
1. Academic Patents and Access to Medicines in Developing Countries by Bhaven N. Sampat (paper)
2. The Role of University Technology Transfer Operations in Assuring Access to Medicines and Vaccines in Developing Countries by Lita Nelsen.
3. Working for a Good Clause: Canadian University Negotiates Global Access Licensing Deal for a Drug Reformulation That Could Save Thousands of Lives AUTM Better World Report, pp. 57-60
More readings for this block coming soon!
————————————————
BLOCK 6: Caveats and Criticisms of Current Approaches
Readings (required):
Area A: Importance of Patents
Do Patents for Antiretroviral Drugs Constrain Access to AIDS Treatment in Africa? by Amir Attaran, Lee Gillespie-White, and responses
Area B: Parallel Importation
Resolving dysfunctional pharmaceutical arbitrage and counterfeit drugs through the proposed Pharmaceutical R&D treaty by Kevin Outterson
Parallel Importation: A Threat to Pharmaceutical Innovation? by Jessica Marter-Kenyon and Jolene Wun, p. 41 of the PDF
Readings (suggested):
Area B: Parallel Importation
Pharmaceutical Arbitrage: balancing access and innovation in international prescription drug markets, by Kevin Outterson. Please read p. 1-18.
Leave a Comment so far
Leave a comment
